Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)
ConditionObsessive-Compulsive Disorder
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorStanford University
About this trial
The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.
Eligibility criteria
Qualifiers
Ages 18-65
Meet the criteria for OCD diagnosis
Failed at least 1 prior trial of standard first-line OCD treatment
Agree to the following lifestyle modifications: comply with requirements for fasting prior to the Experimental Session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures.
Disqualifiers
prior naltrexone or ketamine use/exposure
Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician
Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control
the presence of metal in the body that is contraindicated for MRI scans
Trial design
Treatments tested in this trial
- Ketamine
- Naltrexone Pill
- Placebo pill
Treatment groups
150 Participants
are divided into 3 treatment groupsSponsors and collaborators
Stanford University
Lead sponsor
National Institute of Mental Health (NIMH)
Collaborator
Source ClinicalTrials.gov